Chugai Pharmaceutical Co Ltd (CHGCF)
OTHER OTC:CHGCF
Nxt007, Human Coagulation Factor Viii
Hemophilia A
Phase III
Not Yet Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Feb 11, 2026
―
Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Divarasib
Kras G12c Lung Cancer, Non-small Cell Lung Cancer
Phase III
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Jan 20, 2025
Ray121
Immune-Mediated Necrotizing Myopathy (Imnm), Behçet's Syndrome (Bs), Dermatomyositis (Dm), Immune Thrombocytopenia (Itp), Bullous Pemphigoid (Bp), Antiphospholipid Syndrome (Aps)
Phase I
Enrolling By Invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Nov 27, 2024
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Chugai Pharmaceutical Co Ltd (CHGCF) have in its pipeline
CHGCF is currently developing the following drugs: Emicizumab, Nxt007, Nxt007, Human Coagulation Factor Viii, Donq52, Simulated Inadvertent Gluten Exposure Capsule. These drug candidates are in various stages of clinical development as the company works toward FDA approval.